In 2021, together with my co-founders, Prof. Chao Wang, Prof. Ninuo Xia, Dr. Yanqiong Shen, and Dr. Da Chen, we founded RNAlfa, a biotechnology company dedicated to translating advanced drug delivery systems from bench to bedside. Our primary focus is the development of polymer- and lipid-based delivery platforms for the clinical application of mRNA and small-molecule therapeutics.

Headquartered in Hefei, Anhui Province, China, the company is named RNAlfa, reflecting the vision to “Be Alfa in RNA”. Its Chinese name, “阿法纳” also carries the meaning “Be Alfa in Nano-Delivery” with “纳 (Na)” symbolizing “nano”.

To date, RNAlfa has received six Investigational New Drug (IND) approvals from the National Medical Products Administration’s Center for Drug Evaluation (CDE). We are currently conducting one Phase II trial, three Phase I clinical trials, and three investigator-initiated trial (IIT).

Further updates and pipeline details will be shared soon.